Turning Point Presents Results of Repotrectinib in P-I/II TRIDENT-1 Study for the Treatment of Solid Tumors at AACR-NCI-EORTC 2021

 Turning Point Presents Results of Repotrectinib in P-I/II TRIDENT-1 Study for the Treatment of Solid Tumors at AACR-NCI-EORTC 2021

Shots:

  • The P-I/II TRIDENT-1 study evaluates repotrectinib in NTRK-positive TKI-naïve & pretreated advanced solid tumors. The early P-II data use an Aug 26, 2021 cutoff data
  • The preliminary efficacy analysis in both population showed cORR (41% & 48%); 3 patients achieved SD with tumor regression of -21%, -23% & -27% in TKI-naïve; DoR (1.9+ to 7.4+ & 0.9+ to 15.1mos.), duration of treatment (0.9 to 30.7+ & 0.6 to 20.8mos.)
  • In 23 pretreated patients, 13 (57%) had NTRK solvent front mutations; cORR (62%), DoR (0.9+ to 13.7mos.), 3 patients had uPRs, 2 uPRs have been confirmed & 3rd patients were on treatment awaiting, was well tolerated, treatment discontinuation due to TEAEs (11%)

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post